We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eco Animal Health Group Plc | LSE:EAH | London | Ordinary Share | GB0032036807 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 118.00 | 116.00 | 120.00 | 0.00 | 07:31:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chem,fertlizer Minrl Mng,nec | 85.31M | 1.01M | 0.0149 | 79.19 | 79.94M |
TIDMEAH
RNS Number : 9854N
Eco Animal Health Group PLC
04 February 2021
ECO Animal Health Group plc ("ECO")
(AIM: EAH)
Results for the six months ended 30 September 2020
ECO REPORTS A BUOYANT FIRST HALF AND POSITIVE FULL YEAR INDICATIONS
HIGHLIGHTS
Financials
-- Sales at GBP42.5m (2019 restated*: GBP28.3m) -- EBITDA at GBP6.7m (2019 restated*: GBP1.7m) -- Profit before taxation of GBP4.5m (2019 restated profit*: GBP1.1m) -- Profit after taxation of GBP3.9m (2019 restated profit*: GBP1.3m) -- Earnings per share of 3.13p (2019: restated Earnings per share*: 1.68p) -- Cash generated by operations of GBP3.5m (2019 restated*: GBP1.3m) -- Net cash at 30th September 2020 of GBP12.9m (2019: GBP13.4m)
* Prior period figures have been restated to reflect adjustments arising from the March 2020 audit.
Operations
-- Exceptionally strong recovery in China following the African Swine Fever impact in 2019 -- USA recovery following the easing in geopolitical trade tensions between China and the USA -- Latin America performing strongly, led by Brazil
-- New marketing authorisation from the European Medicines Agency for the use of Aivlosin(R) 625 mg/g Water Soluble Granules in pigs for the treatment of Mycoplasma hyopneumoniae
-- Strong trading in the third quarter
Dr Andrew Jones, Non-executive Chairman of ECO Animal Health Group plc, commented:
"This set of results for the first half builds upon the strong trading seen in China during the latter part of last year with an acceleration in sow restocking and an appreciation of the benefits that Aivlosin(R) brings to animal health and productivity. We are pleased to be releasing these Interim results at the same time as the audited final results for March 2020 and together they mark a turning point in the reassessment of the Group's prior accounting. We are experiencing strong forward trading as evidenced by the successive trading updates and we are also excited with the continued new product development successes. The Directors are confident and excited about the future prospects for the business."
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
Contacts:
ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO) Andrew Jones (Chairman) 020 8447 8899 IFC Advisory Graham Herring Zach Cohen 020 3934 6630 N+1 Singer (Nominated Adviser & Joint Broker) Mark Taylor Iqra Amin 020 7496 3000 Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden 020 7418 8900
ECO Animal Health Group plc ("ECO" or "the Group") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
Chairman's statement
I am pleased to report that despite the considerable challenges presented by Covid-19 we report a set of interim results which demonstrate considerable strength in revenue and profitability.
We welcome Dr Frank Armstrong to our Board. Frank joined us on the 1(st) May 2020 and he brings a wealth of experience in life sciences - businesses large and small - and in particular around the areas of management of Research and Development. This is an increasing feature of our business and his experience will add greatly to our future endeavours.
Audit of the Group's results for the Year ended 31st March 2020
We are releasing this Interim statement on the same day as the delayed release of the Annual report for the year ended 31st March 2020. We are pleased that the first audit by our new auditors, BDO, is complete and the thorough review undertaken, together with the comprehensive prior year restatements sets the Group on a positive footing for future periods.
Covid-19
This trading period has coincided with the primary outbreak of Covid-19 in Europe and the USA and necessary transition to remote working and social distancing has by and large been a smooth and uninterrupted process. Certainly in terms of order volumes, reaching customers and the logistics of order fulfilment we could not have hoped for a better process. The adoption of new ways of working and utilising all that modern on-line communication offers has been a great credit to the skills of our staff members, customers and suppliers and on behalf of the Board I would like to express our gratitude to them.
Financial Performance
Revenue was sharply higher in the first six months to 30th September 2020 at GBP42.5 million (30th September 2019 - GBP28.3 million, driven in the main by a resurgence in China. This is further discussed in the Business Performance comments below. At GBP42.5 million this first half period is at roughly the same run-rate with the GBP43.8 million revenue recorded in the second half of the year ended 31st March 2020. Given the historical pattern of second half weighting to revenue this underlines the strength of the revenue performance in this period.
The gross margin in the first six months has been an average of 48%. This is ahead of the full year ended 31st March 2020 (46%) and considerably stronger than that recorded in the six months ended 30th September 2019 (43%). As reported last year the gross margins were negatively impacted in the USA and as a result of the stronger pork market in the USA the margins have recovered to previously seen levels.
Administrative expenses of GBP10.5 million (2019 - GBP7.2 million) were incurred, the increase being associated with variable costs such as performance related bonus accruals, investment in new members of staff and certain exceptional costs.
Research and development expenditure shown on the income statement and together with the amount capitalised represented a cash investment of 10% of revenue in the six months ended 30 September 2020 (17% in the six month period ended 30th September 2019 restated). In response to the Covid-19 pandemic the Board instigated a prioritisation exercise in the R&D portfolio to conserve cash. Additionally, the revenue in the period was ahead of budget which also results in a slightly lower ratio for a budgeted amount of R&D expenditure.
Earnings before interest, tax, depreciation, amortisation, share based payments and foreign exchange movements ("Adjusted EBITDA") were GBP6.7 million (2019 restated: GBP1.7 million). This increase in profitability was directly a result of the higher revenue at greater gross margins and partially offset by increased R&D investment and overheads.
Cash generated from operations was GBP3.5 million (2019: GBP1.3 million). This was a particularly strong performance which was inline with the cash generated in 2019 allowing for an element of inventory build which was planned ahead of Brexit.
Net cash at 30th September 2020 was GBP12.9 million (31st March 2020: GBP9.8 million). The higher cash position arose from stronger trading and judicious control of cash expenditure in the midst of uncertainty surrounding Covid-19 and its impact on world economies. This consolidated cash position at 30th September 2020 includes GBP9.7 million (March 2020 - GBP5.3 million) which is held in the Group's subsidiary in China. A portion of this cash is repatriated from China once per annum by dividend declaration; the Group's share which is received in the UK is 51%.
Business Performance
The geographical analysis of the Group's revenue in the six months ended 30th September 2020 compared to the prior period in 2019 and the full year ended 31st March 2020 was as follows:
6 months ended 30th Revenue Summary September Year ended 31(st) March 2020 2019 2020 % change (GBP'm) (GBP'm) (GBP'm) 2019 to 2020 Restated Restated China and Japan 20.8 7.0 23.1 197% North America (USA and Canada) 6.4 3.6 11.6 78% South and South East Asia 4.0 7.1 14.2 (44%) Latin America 6.4 5.1 12.6 25% Europe 4.1 4.7 7.6 (13%) Rest of World and UK 0.8 0.8 3.0 0% 42.5 28.3 72.1 50% -------------------------------- ---------- ---------- ----------- -------------
Group revenue improved by 50% to GBP42.5 million compared to the prior period in 2019 - a period which continued to be dominated by the unprecedented impact of Covid-19.
The recovery from ASF in China has been widely reported. The rate of restocking of the pig herd has been ahead of most predictions; the strong pork commodity price driving a number of mechanisms to increase the number of breeding sows and resulting in extraordinary farm profitability. This is turn has resulted in the greater use of premium medications such as Aivlosin(R). It is believed that the efficacy benefits that new users have experienced will result in a number of new, long term, customers.
Revenue in North America, USA in particular, has been strong with a return to pre-2019 levels of business and margins. This has been a result of a normalisation in pork prices in that market as well as export markets (China) becoming available.
India had a steady six months; the poultry market has been badly affected during the Covid-19 pandemic but commentators are expecting a recovery during 2022.
Brazil continues to record strong revenue resulting from a buoyant domestic and export swine market as well as an effective in-country distributor.
Research and Development
In our core product area, a marketing authorisation was obtained from the European Medicines Agency for the use of Aivlosin(R) Water Soluble Granules in the treatment of pigs for Mycoplasma hyopneumoniae. This, together with the equivalent authorisation in the USA and Canada received in January 2021 further demonstrates the strength and depth of our cornerstone product family and the "evergreening" of the Group's core offering.
The Group will continue to invest in building a product pipeline targeting both viral and bacterial diseases of economic importance in pigs and poultry, with the intention of developing a range of vaccines and new products to complement our existing antimicrobial business. The product pipeline contains a mix of well-established concepts as well as novel, potentially disruptive technologies and approaches. These are in various stages of development thereby ensuring that the Group has several mid and late stage projects able to deliver revenues from 2022/23. We were very pleased to announce the approval of the first of these vaccine projects - this was received in January 2021 in Brazil and is for the combined vaccination of pigs against Porcine Circovirus Type2 and Mycoplasma hyopneumoniae.
Brexit
The Group has successfully transferred all EU marketing authorisations to a new European subsidiary, ECO Animal Health Europe Limited with a registered address in Dublin, Republic of Ireland. All contingency planning is in place and the financial and operational impact of Brexit is expected to be minimal.
Prior to 31(st) December 2020, the vast majority of orders for delivery in the first quarter of the calendar year 2021 were delivered to insulate the Group from any possible effects of logistical issues, port delays and transport interruptions.
Dividend
The directors recognise the importance of the dividend to shareholders. However, having due regard to the Group's significant investment in new product development, operating cash flow, and cash balances, the directors consider it prudent to defer the declaration of a dividend at this time.
Outlook
Performance so far in the current financial year ending 31st March 2021 has been strong with the strength seen in both our Chinese and US markets continuing into the second half of our current financial year. In October 2020, we announced that n otwithstanding the historical second half weighting to the Group's revenue, if the first half revenue trends continued through the second half of the financial year the Board expected that the Group's full year revenue for the year ending 31st March 2021 would exceed market expectations. This resulted in an upgraded market expectation both for revenue and profitability.
On 24th November 2020 we confirmed that strong trading had continued during November and, being mindful of the continuing global uncertainties and four months remaining until the end of the financial year, we were confident of meeting the upgraded market expectations.
On 21st January 2021 we issued a positive trading update, confirming Group revenues and EBITDA were expected to be significantly ahead of market expectations for the year ending 31st March 2021. We noted that the strength in the Chinese market, supported by the rebuilding of pig herds and the high price for pork, continued through the third quarter and the outlook for the final quarter sales continued these strong trading trends.
We look forward to the rest of this financial year and our reporting prospects for 2021 with continuing optimism.
Dr Andrew Jones
Non-Executive Chairman
3 February 2021
CONSOLIDATED INCOME STATEMENT FOR THE SIX MONTHS TO 30th SEPTEMBER 2020 Six months Six months Year ended to 30.09.20 to 30.09.19 31.03.20 Notes (unaudited) (unaudited) (audited) GBP000's GBP000's GBP000's Restated* Revenue 4 42,530 28,316 72,106 Cost of sales (22,098) (16,197) (38,742) ----------------------- --------------------- --------------------- Gross Profit 20,432 12,119 33,364 Other income 397 8 105 Administrative expenses (10,524) (7,154) (16,991) R&D expense (4,093) (3,563) (8,775) Currency profits/(losses) (843) 714 (539) Amortisation of intangible assets (789) (821) (1,685) Share based payments (85) (208) (284) ----------------------- --------------------- --------------------- Profit from operating activities: 4,495 1,095 5,195 Net finance cost (39) (4) (30) Share of profit of associate - 42 42 ----------------------- --------------------- --------------------- Profit before income tax 4,456 1,133 5,207 Income tax benefit/(charge) (598) 130 (1,032) ----------------------- --------------------- --------------------- Profit for the period 3,858 1,263 4,175 ----------------------- --------------------- --------------------- Attributable to: Owner of parent company 2,113 1,133 2,582 Non-controlling interest 1,745 130 1,593 ----------------------- --------------------- --------------------- 3,858 1,263 4,175 ======================= ===================== ===================== Earnings per share (pence 2019 - restated) 6 3.13 1.68 3.82 Diluted earnings per share (pence - restated) 6 3.01 1.67 3.67 Earnings before interest, taxation, depreciation, amortisation and share based payments (EBITDA) 5,838 2,408 7,823 Exclude foreign exchange differences 843 (714) 539 Adjusted EBITDA excluding foreign exchange differences 6,681 1,694 8,362 ======================= ===================== ===================== *Details of the restatement, which is unaudited, is presented in Note 3. CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Six months Six months Year ended to 30.09.20 to 30.09.19 31.03.20 (unaudited) (unaudited) (audited) GBP000's GBP000's GBP000's Restated* Profit for the period 3,858 1,263 4,175 Other Comprehensive income/(losses) (net of related tax effects): Items that will or may be reclassified to profit/(loss) in future periods: Revaluation of freehold property - - (92) Adjustment for intangible assets - note 3 - 835 -
Adjustment to tax rates on previously reported adjustments - note 3 - (617) - Foreign currency translation differences 507 47 98 Items that will not be reclassified: Defined benefit plan - actuarial losses - - 12 Other comprehensive income/(losses) for the period 507 265 18 ---------------------- ---------------------- --------------------- Total comprehensive income for the period 4,365 1,528 4,193 Attributable to: Owners of the parent Company 2,651 1,424 2,561 Non-controlling interest 1,714 104 1,632 4,365 1,528 4,193 ====================== ====================== ===================== *Details of the restatement, which is unaudited, is presented in Note 3. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Foreign Minority Share Share Revaluation Other Exchange Retained Total Total Capital Premium Reserves Reserves Reserve Earnings Interest Equity Account Account GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's FOR THE YEARED 31 MARCH 2020 Balance as at 31 March 2019 3,372 62,650 664 106 467 17,214 84,473 5,102 89,575 Profit for the year - - - - - 2,582 2,582 1,593 4,175 Other comprehensive income: Foreign currency differences - - - - 59 - 59 39 98 Revaluation of freehold - - (92) - - - (92) - (92) Actuarial (losses) on pension scheme assets - - - - - 12 12 - 12 Total comprehensive income for the year - - (92) - 59 2,594 2,561 1,632 4,193 ------------- --------------- ------------------ --------------- --------------- -------------- ------------- ------------- ------------ Transactions with owners recorded directly in equity: Issue of shares in the year 5 232 - - - - 237 - 237 Share-based payments - - - - - 284 284 - 284 Deferred tax on share-based payments - - - - - (373) (373) - (373) Dividends - - - - - (7,453) (7,453) (968) (8,421) Transactions with owners 5 232 - - - (7,542) (7,305) (968) (8,273) ------------- --------------- ------------------ --------------- --------------- -------------- ------------- ------------- ------------ Balance as at 31 March 2020 3,377 62,882 572 106 526 12,266 79,729 5,766 85,495 ============= =============== ================== =============== =============== ============== ============= ============= ============ FOR THE SIX MONTHSED 30 SEPTEMBER 2020 Profit for the period - - - - - 2,113 2,113 1,745 3,858 Other comprehensive income: Foreign currency differences - - - - 538 - 538 (31) 507 Total comprehensive income for the period - - - - 538 2,113 2,651 1,714 4,365 ------------- --------------- ------------------ --------------- --------------- -------------- ------------- ------------- ------------ Transactions with owners recorded directly in equity: Issue of shares in the period - 6 - - - - 6 - 6 Share-based payments - - - - - 85 85 - 85 Total transactions with owners - 6 - - - 85 91 - 91 ------------- --------------- ------------------ --------------- --------------- -------------- ------------- ------------- ------------ Balance as at 30 September 2020 3,377 62,888 572 106 1,064 14,464 82,471 7,480 89,951 ============= =============== ================== =============== =============== ============== ============= ============= ============ CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Foreign Minority Share Share Revaluation Other Exchange Retained Total Total Capital Premium Reserves Reserves Reserve Earnings Interest Equity Account Account GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's FOR THE SIX MONTHSED 30 SEPTEMBER 2019 Balance as at 31 March 2019 3,372 62,650 664 106 467 17,214 84,473 5,102 89,575 Profit for the period - as reported - - - - - 1,018 1,018 130 1,148 Prior period adjustments: Adjustment for intangible assets - note 3 - - - - - 115 115 - 115 ------------- --------------- --------------- --------------- ----------------- -------------- ------------- ------------- ------------- Profit for the period - restated - - - - - 1,133 1,133 130 1,263 Other comprehensive income: Adjustment for intangible assets - note 3 - - - - - 835 835 - 835 Adjustment to tax rates on previously reported adjustments - note 3 - - - - - (617) (617) - (617) Foreign currency differences - - - - 73 - 73 (26) 47 Total comprehensive income for the period - - - - -73 1,351 1,424 104 1,528 ------------- --------------- --------------- --------------- ----------------- -------------- ------------- ------------- ------------- Transactions with owners recorded directly in equity: Issue of shares
in the period 5 232 - - - - 237 - 237 Share-based payments - - - - - 208 208 - 208 Dividends - - - - - (7,453) (7,453) - (7,453) Total transactions with owners 5 232 - - - (7,245) (7,008) - (7,008) ------------- --------------- --------------- --------------- ----------------- -------------- ------------- ------------- ------------- Balance as at 30 September 2019 3,377 62,882 664 106 540 11,320 78,889 5,206 84,095 ============= =============== =============== =============== ================= ============== ============= ============= ============= CONSOLIDATED STATEMENT OF FINANCIAL POSITION As at As at As at 30.09.20 30.09.19 31.03.20 (unaudited) (unaudited) (audited) Notes GBP000's GBP000's GBP000's Restated* Non-current assets Intangible assets 7 40,667 41,470 41,439 Property, plant and equipment 2,323 2,044 2,426 Investment property 305 200 305 Right of use assets 1,525 2,043 1,658 Investments 150 166 166 --------------------------- --------------------------- --------------------------- 44,970 45,923 45,994 Current assets Inventories 20,282 20,647 17,264 Trade and other receivables 28,083 19,896 28,353 Income tax recoverable 1,964 1,416 1,265 Other taxes and social security 359 420 652 Cash and cash equivalents 17,058 13,411 11,877 --------------------------- --------------------------- --------------------------- 67,746 55,790 59,411 Total assets 112,716 101,713 105,405 --------------------------- --------------------------- --------------------------- Current liabilities Trade and other payables (16,304) (9,653) (14,486) Borrowings (4,117) - (2,032) Income tax (25) (55) (940) Other taxes and social security - (690) - Amounts due under leases (375) (431) (342) Dividends (50) (4,803) (50) --------------------------- --------------------------- --------------------------- (20,871) (15,632) (17,850) Total assets less current liabilities 91,845 86,081 87,555 Non-current liabilities Deferred tax (686) (309) (636) Amounts due under leases (1,208) (1,677) (1,424) --------------------------- --------------------------- --------------------------- Total assets less total liabilities 89,951 84,095 85,495 =========================== =========================== =========================== Equity Capital and reserves Issued share capital 3,377 3,377 3,377 Share premium account 62,888 62,882 62,882 Revaluation reserve 572 664 572 Other reserves 106 106 106 Foreign exchange reserve 1,064 540 526 Retained earnings 14,464 11,320 12,266 --------------------------- --------------------------- --------------------------- Shareholders' funds 82,471 78,889 79,729 Non-controlling interests 7,480 5,206 5,766 Total equity 89,951 84,095 85,495 =========================== =========================== =========================== *Details of the restatement, which is unaudited, is presented in Note 3. CONSOLIDATED STATEMENT OF CASH FLOWS Six months Six months to to Year ended 30.09.20 30.09.19 31.03.20 (unaudited) (unaudited) (audited) GBP000's GBP000's GBP000's Restated* Cashflows from operating activities Profit before income tax 4,456 1,133 5,207 Adjustment for: Net finance cost 39 4 30 Foreign exchange gain/(loss) (688) (212) 62 Depreciation 155 271 334 Revaluation of investment property - - (64) Amortisation of right-of-use assets 187 184 389 Amortisation of intangible assets 789 821 1,685 Pension payments - (29) (59) Share of associate's results - (42) (42) Share-based payments 85 208 284 --------------------------- ------------------------------ ------------------------ Operating cash flow before movement in working capital 5,023 2,338 7,826 Change in inventories (3,018) (1,002) 2,212 Change in receivables 563 3,278 (5,209) Change in payables 952 (3,313) 662 --------------------------- ------------------------------ ------------------------
Cash generated from operations 3,520 1,301 5,491 Finance costs (40) 41 (17) Income tax (116) (770) (1,076) --------------------------- ------------------------------ ------------------------ Net cash from operating activities 3,364 572 4,398 =========================== ============================== ======================== Cash flows from investing activities Acquisition of property, plant and equipment (231) (85) (767) Disposal of property, plant and equipment - - - Purchase of intangibles (17) (1,282) (2,115) Finance income 64 51 112 Net cash (used in) investing activities (184) (1,316) (2,770) --------------------------- ------------------------------ ------------------------ Cash flows from financing activities Change in borrowings 2,085 - 2,032 Proceeds from issue of share capital 6 237 237 Interest paid on lease liabilities (63) (70) (125) Principal paid on lease liabilities (182) - (364) Finance lease repayments - (273) - Dividends paid - (2,699) (8,421) --------------------------- ------------------------------ ------------------------ Net cash (used in) financing activities 1,846 (2,805) (6,641) --------------------------- ------------------------------ ------------------------ Net (decrease)/increase in cash and cash equivalents 5,026 (3,549) (5,013) Foreign exchange movements 155 97 27 Balance at the beginning of the period 11,877 16,863 16,863 Balance at the end of the period 17,058 13,411 11,877 =========================== ============================== ======================== Free cash flow 3,180 (744) 1,628 --------------------------- ------------------------------ ------------------------ *Details of the restatements, which are unaudited, are presented in Note 3.
NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2020
1. Basis of preparation
The financial information for the period to 30 September 2020 does not constitute statutory accounts as defined by Section 435 of the Companies Act 2006. It has been prepared in accordance with the accounting policies set out in, and is consistent with, the audited financial statements for year ended 31 March 2020.
The Group applies revised IAS 1 "Presentation of Financial Statements (2007)". As a result, the Group presents all non-owner changes in equity in consolidated statements of comprehensive income and all owner changes in equity in consolidated statements of changes in equity.
These Interim Statements have not been audited or reviewed by the Group's auditors.
2. Statement of compliance
This interim financial statement is prepared in accordance with IAS 34 "Interim Financial Reporting". Accordingly, whilst the interim statements have been prepared in accordance with IFRS, and the primary statements follow the format of the annual financial statements, only selected notes are included - those that provide an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the last annual reporting date. IAS 34 states a presumption that anyone who reads the Group's interim report will also have access to its most recent annual report. Accordingly, annual disclosures are not repeated in these interim condensed reports.
3. Changes to significant accounting policies and other restatements
The principal accounting policies which are adopted by the Group in the preparation of its financial statements are set out in in the consolidated financial statements of the Group for the year ended 31 March 2020. These policies have been consistently applied to all prior years. Where necessary, and as detailed in the consolidated financial statements of the Group for the year ended 31 March 2020, any corrections to the application of the Group's accounting policies to comply with International Financial Reporting Standards have been made as restatements of prior period financial statements for the correction of errors in accordance with IAS8 . The correct application of the Group's accounting policies in accordance with IFRS continued into the six months ended 30 September 2020.
Since the September 2019 interim accounts the group has completed its review of the capitalization of historic development expenditure, and reviewed the amortization policy applied to such assets. This has had the effect of increasing the net book value of intangible assets held at September 2019. Full details are given in the Annual Report and Accounts for the year ended 31 March 2020, but the financial effect is summarized below.
Development costs adjustment: Impact on the Balance Sheet and Income Statement
Adjustment Adjustment to retained through Income As reported earnings Statement Restated Sept 2019 Sept 2019 GBP000's GBP000's GBP000's GBP000's Balance sheet Cost 44,922 (3,900) (270) 40,752 Accumulated amortisation (23,004) 4,735 385 (17,884) Net Book Value 21,918 835 115 22,868 ============== ============= ================ ============= Income Statement As reported Adjustment Adjustment Restated for for 6 months to retained through Income 6 months to to Sept 2019 earnings Statement Sept 2019 GBP000's GBP000's GBP000's GBP000's R&D Expense 3,293 - 270 3,563 Amortisation charge 1,206 - (385) 821 -------------- ------------- ---------------- ------------- (115) ================
NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2020 (Continued)
3. Changes to significant accounting policies and other restatements (continued)
In addition, during the completion of the audit of the Group's financial statements for the year ended 31 March 2020 the Group identified some amendments that needed to be made to previously reported prior year adjustments. These amendments arose in respect of changes to the tax rates applied to the previously reported adjustments. The effect of these changes is reported in the Consolidated Statement of Changes in Equity that forms part of these results, and full details are contained in the Group's Annual Report and Accounts for the year ended 31 March 2020.
4. Revenue is derived from the Group's animal pharmaceutical businesses. 5. Principal risks and uncertainties
These were set out on pages 20-22 of the Group's Annual Report and Accounts for the year ended 31 March 2020. The key exposures are to foreign currency exchange rates, potential delays in obtaining marketing authorisations, single sources of supply for some raw materials and trade debtor recovery and have remained unchanged since the year end. In addition, the Annual Report and Accounts highlighted disease impact to growth in emerging markets as a key risk and this, in the form of ASF, is a principal uncertainty.
6. Earnings per share Six months Six months Year ended to 30.09.20 to 30.09.19 31.03.20 (unaudited) (unaudited) (audited) Restated Weighted average number of shares in issue (000's) 67,530 67,493 67,530 Fully diluted weighted average number of shares in issue (000's) 70,313 68,092 70,313 Profit attributable to equity holders of the company (GBP000's) 2,113 1,133 2,582 Basic earnings per share (pence) 3.13 1.68 3.82 Fully diluted earnings per share (pence) 3.01 1.67 3.67
NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2020 (Continued)
7. Intangible non-current assets Distribution Development Goodwill rights Costs Total GBP000's GBP000's GBP000's GBP000's Cost At 1 April 2019 - restated 17,930 1,442 39,470 58,842 Additions - restated - - 1,282 1,282 ------------------ ------------------ --------------- --------------- At 30 September 2019 - restated 17,930 1,442 40,752 60,124 Additions - - 833 833 ------------------ ------------------ --------------- --------------- At 31 March 2020 17,930 1,442 41,585 60,957 Additions - - 17 17 ------------------ ------------------ --------------- --------------- At 30 September 2020 17,930 1,442 41,602 60,974 ================== ================== =============== =============== Amortisation At 1 April 2019 - restated 735 17,098 17,833 Charge for the period - restated 35 786 821 ------------------ ------------------ --------------- --------------- At 30 September 2019 - restated - 770 17,884 18,654 Charge for the period - 35 829 864 ------------------ ------------------ --------------- --------------- At 31 March 2020 - 805 18,713 19,518 Charge for the period - 35 754 789 ------------------ ------------------ --------------- --------------- At 30 September 2020 - 840 19,467 20,307 ================== ================== =============== =============== Net Book Value At 30 September 2020 17,930 602 22,135 40,667 ================== ================== =============== =============== At 31 March 2020 17,930 637 22,872 41,439 ================== ================== =============== =============== At 30 September 2019 - restated 17,930 672 22,868 41,470 ================== ================== =============== =============== At 1 April 2019 - restated 17,930 707 22,372 41,009 ================== ================== =============== ===============
This financial information was approved by the board on 3 February 2021.
Copies of this interim report are being sent to all the Company's shareholders.
DIRECTORS AND OFFICERS Andrew Jones (Non-Executive Chairman) Marc Loomes (Chief Executive) Chris Wilks (Chief Financial Officer) Anthony Rawlinson (Non-Executive Director) Frank Armstrong (Non-Executive Director) REGISTERED OFFICE 78 Coombe Road, New Malden, Surrey. KT3 4QS Tel: 020 8447 8899 COMPANY NUMBER 01818170 INFORMATION AT www.ecoanimalhealthgroupplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR ZZGGZVDRGMZG
(END) Dow Jones Newswires
February 04, 2021 02:02 ET (07:02 GMT)
1 Year Eco Animal Health Chart |
1 Month Eco Animal Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions